A Phase 2 interventional study of B244 and Vehicle in Prehypertension and Hypertension, Stage I, sponsored by AOBiome LLC. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-15.
Sponsored by AOBiome LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Prehypertension with a site in United States — 6 open to participants now, 7 under way, 1 of them phase 3. Prehypertension · United States.
Among the 82 studies in Prehypertension with a site in United States, this one is the 13th largest by enrollment of the 76 interventional ones that give a count, is one of 7 that started in 2016, is one of 7 in phase 2, and was the 48th registered.
158 studies on the registry are indexed under Prehypertension; 21 are open to participants now.
Browse Prehypertension studies →6 of the 82 studies in Prehypertension with a site in United States are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, China and 9 more countries
Ages 18+
University of Hartford · Sites in United States
Ages 18–55 · Healthy volunteers
Duke University · Sites in United States
Ages 6–14 · Healthy volunteers
Duke University · Sites in United States
Ages 12–17 · Healthy volunteers
Emory University · Sites in United States
Ages 18–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Prehypertension studies recruiting now, 3 (27%) set no upper age limit and 7 (64%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 2 · Phase 4 8
First in 2004; this study’s year is marked. 7 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 132 is above the median of 66 across 138 interventional studies indexed under Prehypertension.
Median enrollment 60 across the 76 interventional studies, 130 across the 6 observational. Of the 66 that completed or were terminated, 13 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 82 have an industry lead sponsor. The 10 most frequent:
AOBiome LLC is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AOBiome LLC has 1 study filed under Prehypertension — fewer than ten, so there is no comparison to draw.
2 of the studies in Prehypertension with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07453550University of HartfordThe Effects of Brief Periods of Exercise on Blood Pressure | 2026-12 |
| NCT06595251Duke UniversityCommunity Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study | 2027-05-17 |
Add all 2 to your calendar (.ics) → With an account.
Among the 82 studies in Prehypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate and compare the efficacy of B244 in treating patients with hypertension.
This is a Prospective, Vehicle Controlled, Double Blinded, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 4 weeks vs vehicle application on BP and inflammatory biomarkers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of elevated Blood Pressure defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
Biological: B244
8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
Biological: B244
4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
Biological: Vehicle
8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
Biological: Vehicle
odorless suspension
odorless suspension
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
Safety and tolerability endpoints will consist of all treatment related adverse events reporting during the study duration.
Time frame: Baseline-6 weeks
Difference in Mean in Clinic Systolic BP Between the Active and Vehicle Groups
Clinical systolic blood pressure (BP) readings were obtained at every visit using a calibrated electronic sphygmomanometer. Three measurements were taken at each visit. The average of the second and third readings was documented. Data was analyzed using mixed-effects model repeated measures (MMRM). Difference was calculated as the change from Baseline to Day 28.
Time frame: Baseline-Week 4
Difference in Mean in Clinic Diastolic BP Between the Active and Vehicle Group
Clinical diastolic blood pressure (BP) readings were obtained at every visit using a calibrated electronic sphygmomanometer. Three measurements were taken at each visit. The average of the second and third readings was documented. Data was analyzed using mixed-effects model repeated measures (MMRM). Difference was calculated as the change from Baseline to Day 28.
Time frame: Baseline-Week 4
Difference in Mean Ambulatory Systolic and Diastolic Daytime Blood Pressure
An ambulatory blood pressure measurement (ABPM) device was placed on a subject's arm during the clinic visit to record 24-hour blood pressure and heart rate measurements.
Time frame: Baseline-Week 4
Difference in Inflammatory Biomarkers Between Active and Vehicle Groups
To evaluate if B244 administration on the skin twice daily will affect the levels of immune biomarkers.
Time frame: Baseline-Week 4
Microbial Content
Evaluate if B244 administration on skin twice daily will affect the microbial content on collected skin swab samples.
Time frame: Baseline, Day 28, Day 42
Microbial Composition
Evaluate if B244 administration on skin twice daily will affect the microbial composition on collected skin samples.
Time frame: Baseline, Day 28, Day 42
| Milestone | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Vehicle 4 Pumps Applied to the Face | Vehicle 8 Pumps Applied to Face and Torso |
|---|---|---|---|---|
| Started | 33 | 33 | 33 | 33 |
| Completed | 29 | 30 | 31 | 28 |
| Not completed | 4 | 3 | 2 | 5 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 | 3 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 1 |
| Withdrew: Unplanned travel, family emergency, sponsor request, work schedule | 2 | 1 | 0 | 1 |
Safety and tolerability endpoints will consist of all treatment related adverse events reporting during the study duration.
| Participants | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Pooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps) |
|---|---|---|---|
| At Least 1 Treatment Related TEAE | 1 | 1 | 4 |
| At Least 1 Treatment Related Serious TEAE | 0 | 0 | 0 |
Clinical systolic blood pressure (BP) readings were obtained at every visit using a calibrated electronic sphygmomanometer. Three measurements were taken at each visit. The average of the second and third readings was documented. Data was analyzed using mixed-effects model repeated measures (MMRM). Difference was calculated as the change from Baseline to Day 28.
| mmHg | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Pooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps) |
|---|---|---|---|
| Difference in Mean in Clinic Systolic BP Between the Active and Vehicle Groups | -2.61 ± 1.828 | -0.66 ± 1.834 | -2.93 ± 1.296 |
Clinical diastolic blood pressure (BP) readings were obtained at every visit using a calibrated electronic sphygmomanometer. Three measurements were taken at each visit. The average of the second and third readings was documented. Data was analyzed using mixed-effects model repeated measures (MMRM). Difference was calculated as the change from Baseline to Day 28.
| mmHg | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Pooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps) |
|---|---|---|---|
| Difference in Mean in Clinic Diastolic BP Between the Active and Vehicle Group | -1.65 ± 1.377 | -2.25 ± 1.358 | -1.31 ± 0.975 |
An ambulatory blood pressure measurement (ABPM) device was placed on a subject's arm during the clinic visit to record 24-hour blood pressure and heart rate measurements.
| mmHg | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Pooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps) |
|---|---|---|---|
| Systolic Blood Pressure | -3.06 ± 9.388 | -0.21 ± 12.250 | -0.53 ± 7.619 |
| Diastolic Blood Pressure | -2.17 ± 5.327 | -0.82 ± 7.325 | -0.98 ± 5.911 |
To evaluate if B244 administration on the skin twice daily will affect the levels of immune biomarkers.
| units on a scale | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Pooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps) |
|---|---|---|---|
| Difference in Inflammatory Biomarkers Between Active and Vehicle Groups | NA ± NA | NA ± NA | NA ± NA |
Evaluate if B244 administration on skin twice daily will affect the microbial content on collected skin swab samples.
No measurements were reported for this outcome.
Evaluate if B244 administration on skin twice daily will affect the microbial composition on collected skin samples.
No measurements were reported for this outcome.
Collected over Baseline-Week 6. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B244 4 Pumps Applied to the Face | 0/33 (0%) | 0/33 (0%) | 4/33 (12.1%) |
| B 244 8 Pumps Applied to Face and Torso | 0/33 (0%) | 1/33 (3%) | 6/33 (18.2%) |
| Pooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps) | 0/66 (0%) | 0/66 (0%) | 11/66 (16.7%) |
| Event | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Pooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps) |
|---|---|---|---|
| Exacerbation of depressionPsychiatric disorders | 0/33 | 1/33 | 0/66 |
| Event | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Pooled Vehicle 4 or 8 Pumps Applied to the Face (and Torso for 8 Pumps) |
|---|---|---|---|
| HeadacheNervous system disorders | 1/33 | 0/33 | 3/66 |
| DizzinessNervous system disorders | 1/33 | 0/33 | 2/66 |
| SciaticaNervous system disorders | 0/33 | 1/33 | 1/66 |
| Glycosylated haemoglobin increasedInvestigations | 1/33 | 0/33 | 1/66 |
| Weight increasedInvestigations | 1/33 | 0/33 | 2/66 |
| Dry skinSkin and subcutaneous tissue disorders | 0/33 | 1/33 | 1/66 |
| PruritusSkin and subcutaneous tissue disorders | 1/33 | 0/33 | 0/66 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/33 | 1/33 | 0/66 |
| ArrhythmiaCardiac disorders | 0/33 | 1/33 | 0/66 |
| PyrexiaGeneral disorders | 0/33 | 1/33 | 0/66 |
Intent to Treat Population (ITT): All randomized subjects, analyzed according to treatment assigned.
| Age, Customized(Participants) | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Vehicle 4 Pumps Applied to the Face | Vehicle 8 Pumps Applied to Face and Torso | Total |
|---|---|---|---|---|---|
| <60 years | 25 | 23 | 25 | 27 | 100 |
| ≥60 years | 8 | 10 | 8 | 6 | 32 |
| Sex: Female, Male(Participants) | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Vehicle 4 Pumps Applied to the Face | Vehicle 8 Pumps Applied to Face and Torso | Total |
|---|---|---|---|---|---|
| Female | 15 | 17 | 13 | 17 | 62 |
| Male | 18 | 16 | 20 | 16 | 70 |
| Ethnicity (NIH/OMB)(Participants) | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Vehicle 4 Pumps Applied to the Face | Vehicle 8 Pumps Applied to Face and Torso | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 6 | 11 | 12 | 38 |
| Not Hispanic or Latino | 24 | 27 | 22 | 21 | 94 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Vehicle 4 Pumps Applied to the Face | Vehicle 8 Pumps Applied to Face and Torso | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 0 | 2 |
| Asian | 0 | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 13 | 6 | 9 | 36 |
| White | 23 | 19 | 26 | 22 | 90 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 | 2 |
| Weight(kg) | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Vehicle 4 Pumps Applied to the Face | Vehicle 8 Pumps Applied to Face and Torso | Total |
|---|---|---|---|---|---|
| Mean | 89.32 ± 21.084 | 89.04 ± 21.654 | 86.56 ± 12.251 | 88.59 ± 18.871 | 88.38 ± 18.654 |
| BMI(kg/m^2) | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Vehicle 4 Pumps Applied to the Face | Vehicle 8 Pumps Applied to Face and Torso | Total |
|---|---|---|---|---|---|
| Mean | 30.139 ± 6.2438 | 30.427 ± 5.9047 | 29.306 ± 4.3707 | 30.304 ± 6.3886 | 30.044 ± 5.7332 |
| BMI Category(Participants) | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Vehicle 4 Pumps Applied to the Face | Vehicle 8 Pumps Applied to Face and Torso | Total |
|---|---|---|---|---|---|
| <30 kg/m^2 | 19 | 16 | 20 | 22 | 77 |
| ≥30 kg/m^2 | 14 | 17 | 13 | 11 | 55 |
| Smoking History(Participants) | B244 4 Pumps Applied to the Face | B 244 8 Pumps Applied to Face and Torso | Vehicle 4 Pumps Applied to the Face | Vehicle 8 Pumps Applied to Face and Torso | Total |
|---|---|---|---|---|---|
| Never | 19 | 22 | 22 | 19 | 82 |
| Former | 6 | 7 | 6 | 3 | 22 |
| Current | 8 | 4 | 5 | 11 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2016 to primary completion in Apr 2017, 5 months.
Results were first posted in Aug 2022, 5 years 3 months after primary completion. A results delay was requested in Jul 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitrosomonas eutropha D23
AOBiome LLC